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0.229 (p = 0.0013). The 2- and 5-year recurrence-free sur-
vival rates were 68.5, 41.4 and 56.8, 26.2 % in groups A 
and B, respectively. Those differences were also statisti-
cally significant (log-rank test p = 0.0020). The HR was 
0.423 (p = 0.0027) in favor of group A. As for adverse 
reactions to immunotherapy, of a total of 762 courses, 52 
(6.8 %) were accompanied with chills and shivering, and 
47 (6.2 %), with fever (>38 °C).
Conclusions Immunotherapy has the potential to improve 
the postsurgical prognosis of lung cancer patients, but a 
large-scale multi-institutional RCT is awaited for further 
confirmation of this study.
Keywords Phase III study · Lung cancer · Adjuvant 
therapy · Immunotherapy · Lymph node · Dendritic cell
Abbreviations
AKT-DC  Activated killer T cells and dendritic cells
ALK  Anaplastic lymphoma kinase
CDTC  Circulating and disseminating tumor cells
CI  Confidence interval
CR  Complete response
EGFR  Epidermal growth factor receptor
HR  Hazard ratio
LAK  Lymphokine-activated killer T cells
NSCLC  Non-small cell lung cancer
PR  Partial response
TDLN  Tumor-draining regional lymph nodes
TKI  Tyrosine kinase inhibitor
Introduction
Lung cancer is the leading cause of cancer deaths in many 
advanced countries. Although molecular targeted therapy 
Abstract 
Purpose We conducted a phase III randomized controlled 
trial (RCT) to investigate the efficacy of postsurgical adju-
vant immunotherapy combined with chemotherapy. The 
immunotherapy targets were residual micrometastases and 
clones resistant to chemotherapy.
Patients and methods Between April 2007 and July 2012, 
103 postsurgical non-small cell lung cancer patients were 
randomly assigned to receive either chemo-immunotherapy 
(group A) or chemotherapy (group B). The immunotherapy 
consisted of the adoptive transfer of autologous activated 
killer T cells and dendritic cells obtained from the lung 
cancer patients’ own regional lymph nodes.
Results The 2-year overall survival rates in groups A and 
B were 93.4 and 66.0 %, and the 5-year rates were 81.4 
and 48.3 %, respectively. The differences were statistically 
significantly better in group A. The hazard ratio (HR) was 
This study was presented in part at the 15th World Conference on 
Lung Cancer on October 27–30, 2013, in Sydney, Australia.
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and new anticancer drugs have improved the prognosis, the 
overall survival rate is still only 20–30 %. Early diagno-
sis and surgery are the best ways to cure lung cancer, but 
most cases are detected at an advanced stage. Only one-
third of patients are in stages I–II and become candidates 
for surgery. Another third receive chemotherapy and/or 
radiotherapy, while the rest are in far advanced stages and 
receive only the best supportive care. Furthermore, more 
than half of the patients, who are supposed to have under-
gone complete resection, subsequently undergo relapse in 
distant organs. One of the reasons for this poor prognosis 
may be the biological nature of lung cancer acquired during 
the course of cancer onset and progression. Intra-tumor het-
erogeneity within the primary tumors [1, 2] of lung cancer 
gives rise to clones resistant to chemotherapy and/or radia-
tion therapy even if the initial response to those treatments 
is effective. Furthermore, a propensity for early dissemina-
tion and metastasis [3, 4] causes relapse after surgery or 
radiotherapy. Platinum-based doublet chemotherapy has 
been reported to improve the prognosis of postsurgical 
patients, but the impact on survival is modest and seems to 
have reached an efficacy plateau in the past decade [5–7].
We conducted a phase III randomized controlled study 
to investigate the efficacy of postsurgical adjuvant chemo-
immunotherapy [8] using autologous activated killer T cells 
and dendritic cells (AKT-DC) [9]. Since most recurrences 
after surgery with adjuvant chemotherapy derive from 
chemotherapy-resistant micrometastases, we targeted resid-
ual micrometastases resistant to chemotherapy.
Patients and methods
Study design and inclusion criteria
Patients with postsurgical non-small cell lung cancer were 
randomly assigned to receive either adjuvant chemo-
immunotherapy (immunotherapy arm: group A) or adju-
vant chemotherapy (control arm: group B) (Fig. 1). Immu-
notherapy consisted of the adoptive transfer of AKT-DC 
derived from the regional lymph nodes of lung cancer 
patients (Fig. 2). Study inclusion criteria were as follows: 
postsurgical patients aged <76; Eastern Cooperative Oncol-
ogy Group (ECOG) performance status (PS) 0–1; adequate 
bone marrow function, liver function, and renal function; 
histology: primary NSCLC (including combined-type small 
cell carcinoma); and pathological stage: IB with tumor 
sizes larger than 5 cm or with severe vessel invasion and 
stages II–IV (TNM staging system version 6). Although the 
indications for thoracotomy are limited to clinical stages 
I–II and stage IIIA after induction chemotherapy, stage 
IIIB and IV cases with malignant pleural effusion, micro-
metastasis to mediastinal lymph nodes or intrapulmonary 
metastasis identified after thoracotomy were also included. 
Non-curative resection cases were included, but explora-
tory thoracotomies or cases with macroscopic residual 
tumors were excluded. The protocol was reviewed and 
approved by the Ethics Committee of Chiba Cancer Center 
and the University Hospital Medical Information Network 
in Japan (UMIN: 000007525). All patients provided written 
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Fig. 1  CONSORT diagram. Out of 556 cases treated surgically 
from April 2007 to July 2012, 103 eligible cases were randomized to 
receive chemo-immunotherapy (group A) or chemotherapy (group B). 
Ineligible cases (1 case each in groups A and B) were excluded, and 
50 and 51 group A and B cases, respectively, were treated




























Fig. 2  Procedure for chemo-immunotherapy. Tumor-draining 
regional lymph nodes (TDLN) with no metastasis were obtained at 
surgery, minced aseptically, and cultured in lymphocyte medium con-
taining IL-2. Activated killer T cells and dendritic cells (AKT-DC) 
released from TDLN were harvested, washed, and transferred to the 
patients every month, beginning 1 week after adjuvant chemother-
apy for 4 courses. Immunotherapy was continued every month for 
6 months and then every 2 months until 2 years after surgery. When 
TDLN stopped releasing AKT-DC, peripheral blood lymphocytes 
obtained by lymphocyte apheresis were added and co-cultured with 
TDLN
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with the ethical principles of the Declaration of Helsinki 
and the International Conference on Harmonization of 
Good Clinical Practice guidelines.
Other inclusion criteria
In addition to the criteria cited above, the results of in vitro 
examination of lymph node activity were also required 
for inclusion in the study. The autologous AKT-DC from 
the regional lymph nodes of patients had to grow enough 
to provide more than 7 × 109 cells for each course of the 
therapy. Exclusion criteria for the study were as follows: 
a positive response to HIV, hepatitis C virus, or human T 
cell lymphotropic virus antibodies; a positive response to 
hepatitis B surface antigen; and evidence of another active 
malignant neoplasm.
Randomization
Before enrolling for randomization after surgery, patients 
were stratified according to their stage, curability, and 
whether or not they received induction chemotherapy. 
Those who had received surgery at first were stratified by 
pathological stage: group I, stage IB; group II, stage II; 
group III, stage IIIA; and group IV, stages IIIB and IV. 
Those who had received induction chemotherapy were 
stratified to group V, stage IIIA and group VI, stages IIIB 
and IV. Those patients whose surgery was expiratory thora-
cotomy or in whom macroscopic residual tumors remained 
after surgery were excluded from the study. Patients with 
microscopic residual tumors detected after pathological 
examinations were included in the study, but were assigned 
to a more advanced stage. For example, stage IIIA patients 
with a positive margin of lymph nodes, a bronchial stump, 
or an arterial stump were stratified to group IV as stages 
IIIB and IV.
After all criteria had been met and written informed 
consent for enrollment in the study had been obtained, 
randomization was performed by the Internet Data and 
Information Center for Medical Research (INDICE) of the 
University Hospital Medical Information Network (UMIN) 
of Japan (file name: CCCI).
Treatment
Those who were allocated to group A (immunotherapy 
arm) received 4 monthly courses of postsurgical chemo-
therapy. Adoptive immunotherapy using AKT-DC was 
added 1 week after each course of chemotherapy and was 
then continued once a month for the first 6 months after 
resection and then every 2 months until 2 years after sur-
gery. This amounted to a total of 12–15 courses in 2 years 
(Fig. 2). Group B (control arm) received four courses of 
postsurgical chemotherapy. Stage IIIA patients received 
two courses of induction chemotherapy before surgery. 
Those patients underwent thoracotomy with extended 
lymph node dissection (ND3α) via median sternotomy 
[10], followed by two courses of chemotherapy.
Chemotherapy regimens
Since no standard regimen had been established in the 
adjuvant setting at the time when this study was designed 
[11–13], we decided to use platinum doublet regimens 
belonging to the third-generation drugs described in Data 
Supplement 1.
Preparation of activated killer T cells and dendritic cells 
from regional lymph nodes
The procedure for the preparation of AKT-DC has been 
described elsewhere [9] (Fig. 2). Tumor-draining lymph 
nodes include those from the intra-pulmonary to the medi-
astinal lymph nodes. We used 1–2 g of regional lymph 
nodes located as near to the primary tumors as possible 
with no metastasis. If there was no metastasis, we used 
intra-pulmonary or hilar lymph nodes, and if metastasis had 
already taken place as far as the mediastinal lymph nodes, 
we chose mediastinal lymph nodes without metastasis.
Halves of the two or three tumor-draining regional 
lymph nodes (TDLN) with no tumor metastasis were 
rinsed with 50 ml of RPMI-1640 medium (Life Technolo-
gies Co., Japan) containing antibiotics, while their other 
halves were submitted for pathological examination for the 
presence of metastasis. Those in which no metastasis was 
found were transferred to a sterile Petri dish and minced 
aseptically into 1-mm3 tissue fragments. Each one showing 
evidence of metastasis was discarded. The tissue prepara-
tion was then suspended in 50 ml KBM-400 (Kojin Bio 
Co., Tokyo, Japan) or Alyse (ALyS505N: Cell Science and 
Technology Institute, Inc., Sendai, Japan) serum-free lym-
phocyte medium containing 400 IU/ml human recombinant 
interleukin 2 (Proleukin; Chiron B.V., Amsterdam, Neth-
erlands), transferred to a 75-cm2 culture flask, and incu-
bated at 37 °C in air containing 5 % CO2. When the TDLN 
started to release AKT-DC—usually 2–3 weeks after the 
initiation of the culture—the tissue and cells were trans-
ferred to a culture bag (lot 130129: NIPRO Osaka, Japan) 
specifically designed for lymph node tissue cultures. Half 
the volume of fresh medium was added every 2–3 days 
as long as the cells continued to proliferate exponentially. 
The AKT-DC generated were separated from the TDLN 
tissue by filtering through a nylon mesh and were then 
transferred to another bag. The TDLN tissue culture was 
continued until the propagation of the cells stopped. The 
AKT-DC suspension was split 2–3 times every 3–4 days 
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into new bags each containing 800 ml of fresh medium. 
Then, cells containing AKT-DC were harvested, washed 
twice using 200 ml of saline suspended in the cryopro-
tective agent CP-1 (Kyokuto Pharm. Co., Tokyo, Japan) 
with 4 % human albumin, and stored, 5–10 × 109 cells/
bag (freeze bag F-100A: NIPRO Osaka, Japan) at −80 °C 
until used. Usually, the TDLN cultures continued to release 
AKT-DC for 2–3 months. When the TDLN stopped releas-
ing cells, 1–2 × 109 peripheral blood lymphocytes (PBL) 
obtained by lymphocyte apheresis with a COBE Spectra 
System (COBE BCT, Inc., Colorado, USA) were added. 
TDLN together with a PBL culture were carried out until 
we obtained a sufficient number of AKT-DC (1–3 × 1011 
cells) for 12–14 courses of immunotherapy.
Certification of cells before transfer to patients
As stated elsewhere, since the cells were cultured in a 
sealed bag using a serum-free medium, contamination with 
bacteria or viruses was prevented, but all the cells under-
went security tests before transfer to the patients. Cell 
viability was tested by Trypan blue dye exclusion meth-
ods, and cells with <90 % viability were discarded. Bac-
terial contamination was tested by skilled examiners with 
light microscopes. Endotoxin tests conducted with an 
endotoxin single test kit (Wako Co., Osaka, Japan) and a 
toxinometer (MT-353: Wako Co.), as well as culture tests, 
were performed whenever bacterial contamination was 
suspected. The cell surface markers were analyzed before 
initiation of the culture and just before freezing at −80 °C 
using two-color methods by FACS analysis with CD3, 4, 
8, 25, 80, 83, B7H1, and HLA-DR monoclonal antibodies 
(Becton–Dickinson Biosciences, CA, USA). Cultures con-
sisting of more than 30 % CD25+CD4+ regulatory T cells 
were discarded before freezing. Tumor cell contamination 
was tested by cytological examination with Papanicolaou 
stain and by immunohistochemical analysis with cytokera-
tin (Dako Japan Inc., Tokyo Japan) or thyroid transcription 
factor-1 (TTF-1 Dako) antibodies.
Transfer to patients
Cells qualified by safety examination, and stored at 
−80 °C, were thawed in a 37 °C water bath and transferred 
to the patients intravenously with 50 ml saline.
End points
The primary end point of this study was overall survival. 
Secondary end points were recurrence-free survival, tox-
icity, and adverse effects of immunotherapy. All eligible 
patients were included in the analysis of overall survival 
and progression-free survival.
Follow-up
Patients received regular checkups with tumor markers 
(CEA, CA-199, SCC, etc.) and chest X-rays every month 
for the first 6 months, every 2–3 months until 2 years had 
passed, and every 4–6 months thereafter until 5 years after 
the thoracotomy. Chest CTs were performed 3, 6, and 
12 months after surgery and every 4–6 months thereafter 
until the 5-year point. One, two, and five years after surgery 
and whenever recurrence was suspected, PET-CT or a bone 
scan and/or a brain MRI was performed.
Diagnosis and treatment after recurrence
Recurrence was diagnosed by the Cancer Board of Tho-
racic Diseases in our center following the preset require-
ments: (1) histological or cytological evidence of recur-
rence discovered by biopsy and (2) tumor marker elevation 
or growth of new lesions accompanied by positive PET 
findings. Temporary elevation of tumor markers or new 
lesions with no apparent growth was not considered to 
show recurrence.
Chemotherapy was used after recurrence, and brain 
metastasis was treated with a gamma knife or by whole-
brain irradiation. Bone or lymph node metastasis was 
treated by radiation. Immunotherapy was continued or 
resumed with the patient’s consent in combination with the 
chemotherapy. EGFR-mutation-positive patients received 
EGFR-TKI and ALK fusion gene-positive patients received 
ALK-TKI.
Sample size
Pretrial assumption of sample size was made according to 
the following formula [14]:
where S1 is the rate of survival of group A at 5 years after 
surgery, and S0 is the rate of survival of group B at 5 years. 
ω represents the rate of dropout and Zα/2 + Zβ = 2.8018 
(from the table of normal distribution). We have set the 
two-sided significance level at 5 % with the power of the 
test at 80 %.
From the phase II study conducted between 1998 and 
2004, it was estimated that 45 patients would be required 
per arm of the study. Taking into account the possibility 
of more dropout and death cases, we planned to enroll 60 
cases per arm for 5 years.
N = [ε/2− S1− S0]/(1− ω)
ε = [(θ + 1)/(θ − 1)]2(Zα/2 + Zβ
)2
θ = log(S1)/log(S0)
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Statistical analysis
Statistical analysis was performed on all randomly assigned 
eligible patients. Overall survival was defined as the time 
from random assignment to the date of death from any 
cause. Recurrence-free survival was defined as the time 
from randomization until the confirmation of recurrence by 
our Cancer Board. Survival curves were estimated by the 
Kaplan–Meier technique. Duration of survival was com-
pared between the treatment arms using a two-sided log-
rank test. All data analyses were performed using Statistical 
Analysis Software version 9.3 (Statcom Co., Ltd., Tokyo, 
Japan) by the Translational Research Informatics Center 
(TRI) of the Ministry of Education, Culture, Sports, Sci-
ence and Technology of Japan, and by the Foundation for 
Biomedical Research and Innovation in Kobe City. Interim 
analysis was scheduled for 5 years after the initiation of the 
study, regardless of the time of enrollment.
Results
The study opened on April 1, 2007 and closed on July 30, 
2012. Of a total of 556 patients who underwent surgery for 
lung cancer in our center, 103 cases were enrolled in the 
study, and 453 cases were ineligible and excluded from it: 
110 patients were over 76 years old, 226 cases were stage IA, 
46 cases were stage IB with tumor sizes of <5 cm, 35 were 
stage IIIB, IV with macroscopic residual tumors remaining 
after surgery and failed to provide enough T cells, 29 had a 
PS of ≧2, and 7 patients refused randomization (Fig. 1). The 
demographic characteristics of the patients were evenly dis-
tributed between the two groups (Table 1). Projected accrual 
was 120 cases, but enrollment was stopped at 103 cases in 
July 2012 on the basis of interim analyses conducted after 
5 years. Significant survival benefit was observed in group 
A, and we felt that further continuation of the study with the 
group B control arm would be unethical. The median follow-
up time was 32.2 months. Among the patients enrolled for 
the study, two were found to be ineligible after randomiza-
tion and were finally excluded from the study.
Surgery and chemotherapy
Induction chemotherapy was administered in 12 and 15 
clinical stage IIIA cases in groups A and B, respectively. 
The types of agents administered in this chemotherapy, as 
well as the surgical procedures, were well balanced in the 
two arms, and there was no statistical difference between 
the groups in the numbers of courses of chemotherapy. 
The chemotherapy regimens of both groups are stated in 
DS1. The mean total numbers of courses of chemotherapy 
including those after recurrences in groups A and B were 
5.80 ± 3.83 (SD) and 6.41 ± 6.65 (SD), respectively. 
EGFR-TKI was given to five patients in group A and to 
seven in group B after recurrences. Eight cases in group A 
and 11 in group B received bevacizumab in combination 
Table 1  Baseline patient demographic and clinical characteristics
Ad Adenocarcinoma, Sq Squamous cell carcinoma, Large Large-cell 
carcinoma, Pleo Pleomorphic carcinoma
Characteristics group A Group B p


































Group I 7 6
Group II 7 6
Group III 13 14
Group IV 11 10 0.5844
Group V 7 9
Group VI 5 6
Total 50 51
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with or without chemotherapy. One patient in group A 
received an ALK fusion gene inhibitor.
Adoptive immunotherapy
A total of 762 courses were administered to group A 
patients from April 2007 to February 2013. The mean 
number of effector cells in each course was 10.2 ± 3.1 
(standard deviation; SD) × 109 cells, the mean number of 
courses for a patient was 15.3 ± 6.92 (SD) courses, and 
the mean total of effector cells delivered was 1.51 ± 0.68 
(SD) × 1011 cells. There was no correlation between the 
number of courses delivered to a patient and either recur-
rence or survival. The courses and the numbers of cells 
delivered to each patient are detailed in DS2.
Adverse reactions to immunotherapy
Out of a total of 762 courses, 52 (6.8 %) were accompanied 
with chills and shivering, and 47 courses (6.2 %) were fol-
lowed by fever (>38). Of 50 patients treated with immuno-
therapy, 28 had no adverse reactions and 22 had at least one 
adverse reaction of chills, shivering and/or fever. Chills and 
shivering started about 30 min after the start of each cell 
transfer, continued for 10–20 min, and were followed by fever 
up to 38–40 °C. These fevers lasted for 2–3 h, and the body 
temperature then gradually declined to a normal level within 
the same day. In no case did fever persist until the next day. 
No adverse reaction other than chills or fever was observed. 
Adverse reactions are listed in DS2 (Data Supplement 2).
Recurrence
There were 19 cases of recurrence in group A (lungs, 6; 
lymph nodes, 5; bones, 3; and others, 5) and 33 in group B 
(lungs, 9; lymph nodes, 8; bones, 8; brain, 5; and others, 3). 
Seven patients in group A became tumor free after recur-
rence following treatments combined with immunotherapy: 
two cases of EGFR-TKI, three cases of resection of lung 
metastasis, one case of ALK fusion gene inhibitor, and 1 of 
radiation; and continued to be tumor free until the time of 
the final analysis. In one case in group B, CR was attained 
after chemotherapy. Therefore, 38 patients in group A and 
19 patients in group B were tumor free at the time of analy-
sis. Recurrence was seen in 14 and 21 cases of adenocar-
cinoma and in 3 and 7 squamous cell carcinoma cases in 
groups A and B, respectively. There was no correlation 
between recurrence and histological types.
Survival
Figure 3 shows the Kaplan–Meier estimates of overall sur-
vival. The 2- and 5-year overall survival rates were 93.4 % 
[95 % confidence interval (CI) 80.8–97.8] and 81.4 % 
(60.1–92.1) in group A, and 66.0 % (50.4–77.7) and 48.3 % 
(31.4–63.3) in group B, respectively. The difference was 
statistically significant (log-rank test p = 0.0005, general-
ized Wilcoxon test p = 0.0005) in group A. The HR was 
0.229 (95 % CI 0.093–0.564, p = 0.0013). The median sur-
vival time of group B was 47.5 (from 26.3 to not reached) 
months and was never reached in group A. The 2- and 
5-year recurrence-free survival rates (Fig. 4) were 68.5 % 
(53.2–79.7) and 56.8 % (40.3–70.3) in group A, 41.4 % 
(27.5–54.7) and 26.2 % (13.1–41.5) in group B, respec-
tively. The difference was statistically significant (log-rank 
test p = 0.0020). HR was 0.423 (95 % CI 0.241–0.743, 
p = 0.0027) in group A. The median recurrence-free sur-
vival was 16.56 (9.00–32.01) months in group B, but was 
not reached in group A.
Fig. 3  Kaplan–Meier estimates of overall survival for groups A and B
Fig. 4  Kaplan–Meier estimates of recurrence-free survival for groups 
A and B
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Discussion
We have reported the results of a phase III randomized 
controlled study of postsurgical adjuvant immunotherapy 
with lymphokine-activated killer (LAK) cells conducted 
between 1986 and 1992 [15]. The in vitro study using 
regional lymph nodes as a source of killer and dendritic 
cells indicated a much higher activity against autolo-
gous tumor cells than that using LAK cells [9]. A phase 
II study was conducted between 1998 and 2004 using 
AKT-DC obtained from the regional lymph nodes of pri-
mary lung cancer patients [16]. The results of the phase II 
study predicted a promising outcome for a phase III study 
using this modality. Furthermore, this modality yielded a 
more marked effect in early stage than in advanced-stage 
cases. Patients with macroscopic residual tumors, such as 
those with pleural dissemination, or bulky N2–N3 metas-
tases, failed to respond to this treatment. Therefore, we 
added stage II cases and IB cases with tumor sizes larger 
than 5 cm to, and excluded cases with macroscopic residual 
tumors from, the present phase III study.
This phase III study, conducted between 2007 and 2012, 
is the concluding portion of a series of studies of adjuvant 
immunotherapy for postsurgical lung cancer patients that 
lasted from 1986 to 2012. In a clinical study conducted 
to verify the effects of chemotherapy, placebo groups are 
included. But in adjuvant settings, control arms do not 
usually use placebo or blinded procedures, but observa-
tion only. The reasons for this originate from the fact that 
there has been no standard chemotherapy recommended 
to improve survival in adjuvant settings. In this adjuvant 
immunotherapy, we thought that blind control with no cell 
infusion would be deceptive and unethical. Furthermore, 
there are no cells which have no effect at all—whether 
favorable or unfavorable—on the immune response.
The successful outcome of this study depended largely 
on the improvements of the in vitro system, which enabled 
us to obtain a large quantity of high-quality effector cells 
for use in each course of treatment. Long-term tissue cul-
tures of lymph nodes in specifically designed culture bags 
enabled us to transfer 1–2 × 1010 cells for a course of treat-
ment in a contamination-free environment. The most effec-
tive dose for immunotherapy remains a matter of conjec-
ture, but the number of lymphocytes and dendritic cells 
transferred to the patients, and their activity against cancer 
cells appear to be the key issues that determine whether 
the immunotherapy will work or not. We obtained suffi-
cient numbers of lymphocytes from N0, N1 patients, but it 
was difficult to do so from some of the N2, N3 patients. In 
half of the N2, N3 patients, usually those with tumors that 
were macroscopically residual, it was difficult to obtain 
sufficient lymphocytes. Among our 62 stage IIIB and IV 
cases, 35 (56.5 %) were excluded from the study because 
macroscopic residual tumors remained after surgery, and 
we could not obtain enough T cells. The cell surface mark-
ers of AKT-DC were CD3 (94.7 %), CD4 (57.9 %), CD8 
(55.1 %) and CD83 (21.5 %) [9]. Although we have not 
evaluated precisely the correlation between cell surface 
markers and the effects of immunotherapy, we could not 
detect any relationship between cell surface markers and 
the results of immunotherapy so far observed.
It has been suggested that immunocompetent cells 
eliminate or suppress the proliferation of nascent trans-
forming cells in the initiation of tumor growth (known as 
the immunoediting: elimination phase) [17–19]. However, 
immune selective pressure favors the growth of tumor 
cell clones with a low-immunogenic phenotype, and this 
leads to the equilibrium phase of immunoediting. In this 
phase, tumor cell generation and apoptosis are equivalent 
and keep the tumor size unchanged in an equilibrium in 
which tumors remain occult and asymptomatic for a pro-
longed period of time [20–22]. In the escape phase, when 
tumors start proliferating, expanding in size, and forming 
clinically detectable masses, the immune system, in turn, 
becomes inefficient or tolerates tumor growth. Numerous 
mechanisms have been proposed to explain how tumors 
escape immune control and find a way from dormancy 
to progression [23–26]. Immunosuppression within the 
tumor microenvironment has been cited as one of the 
causes of the ineffectiveness of immunotherapy against 
cancers [27–30].
The target of the immunotherapy described here is not 
the primary lesion, but the undetectable tumor cells remain-
ing after the resection of a primary carcinoma [3, 4]. A 
major cause of tumor recurrence is metastasis that is con-
sidered to be derived from circulating and disseminating 
tumor cells (CDTC). Primary cancers start releasing tumor 
cells at relatively early stages of tumor development. CDTC 
released from the primary lesion remain dormant and in a 
quiescent state for a prolonged period of time as solitary 
tumor cells or dormant micrometastases [20–22]. A contro-
versial discussion of the main reasons for immune escape 
mechanisms concerns whether tumor growth depends on 
the poor immunogenicity of tumor cells, which helps them 
to escape immune recognition, or on the immunosuppres-
sive mechanisms working within the tumor microenvi-
ronment. In other words, either (1) since the tumor cells 
have already undergone immune surveillance, they are 
not recognized by the immune system and only the non-
immunogenic tumor cells survive after tumor progression, 
or (2) tumor cells are recognized, but immune suppression 
in the tumor microenvironment blocks immune attack by 
killer cells. The results of this study suggest the importance 
of the latter mechanisms of the tumor microenvironment 
in immune escape. Immunotherapy using this modality 
therefore has a role in recurrence control by inhibiting the 
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growth of disseminated micrometastases before an immu-
nosuppressive microenvironment has been achieved.
The majority of the causes of cancer recurrence derive 
from CDTC, which are clinically undetectable at the time 
of surgery. The phenotypic diversity of disseminated cells 
resulting from intra-tumor heterogeneity [1, 2] gives rise to 
clones resistant to chemotherapy and prevents tumor cell 
eradication by chemotherapy. The heterogeneity of tumor 
cells enables them to escape even from molecular tar-
geted therapy [31]. The regional lymph nodes of lung can-
cer patients are the sites where the first adoptive immune 
response against cancer develops [32, 33]. Dendritic cells 
at the tumor site take up antigens, migrate to lymph nodes, 
and educate antigen-specific naïve T lymphocytes to 
become cytotoxic T lymphocytes [34]. Using these lymph 
nodes as a source of dendritic cells and killer cells, we 
can eradicate the heterogeneous tumor cells disseminating 
throughout the body carrying a wide variety of antigens.
Our long experience of in vitro cultures of regional 
lymph nodes [35–37] shows that, although in vitro culture 
of non- or micrometastatic regional lymph nodes induces 
AKT-DC in the presence of low-dose IL2, macroscopic 
metastatic lymph nodes do not propagate those cells in 
vitro. In other words, tumor cells and lymphocytes are 
mutually exclusive and never coexist in vitro when cultured 
in the presence of IL2 for more than 2–3 weeks. There-
fore, contamination of tumor cells in AKT-DC is prohib-
ited when lymphocyte growth is dominant. This in vitro 
phenomenon does not seem to depend on the patient or the 
tumor cell types, but on the reciprocal quantitative balance 
between tumor cells and lymphocytes. This phenomenon 
indirectly provides evidence that tumor cells are recognized 
even after tumor progression, but the tumor microenviron-
ment blocks the effect of immune responses.
The outcome of the present study was successful, and 
this may be attributable to the mechanism whereby the 
target of immunotherapy is the dormant CDTC remaining 
after surgery before an immunosuppressive microenviron-
ment is developed. Although the results of this study have 
great significance, this single-institutional small-sample 
study needs further confirmation with a large-scale multi-
institutional RCT before the clinical importance of this 
modality is fully recognized.
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